Adding nivolumab (Opdivo) to neoadjuvant chemotherapy followed by adjuvant treatment with the PD-1 inhibitor alone significantly increased event-free survival (EFS) for patients with resectable ...

Disparities in Utilization of Immune Checkpoint Inhibitor Therapy Among Older Patients With Advanced Non–Small Cell Lung Cancer: A SEER-Medicare Analysis Adults with previously treated ...

How Does Opdualag Work for Advanced Melanoma? Some cancer cells have what are called checkpoint proteins on their surface. The immune cells in our body also have proteins on their surface. When these ...

Please provide your email address to receive an email when new articles are posted on . Patients who received nivolumab had longer DFS than those who received standard care. OS will be evaluated after ...

Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial Nivolumab plus relatlimab ...

Perioperative nivolumab not only extends event-free survival (EFS) but also does not compromise quality of life in patients with resectable non-small cell lung cancer (NSCLC), including those with ...

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive bladder ...

The FDA's CRL cited the IGNYTE trial's inadequacy and patient heterogeneity as reasons for not supporting RP1's approval. Replimune plans to pursue a Type A meeting to discuss potential accelerated ...

Nivolumab and ipilimumab combination approved for microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC), showing significant progression-free ...

A Prescription Drug User Fee Act target date of June 23, 2025 has been set for the application. The sBLA is supported by data from the randomized, open-label phase 3 CheckMate 8HW trial ...